Martin Babler
Insider Reports History
- Location
- South San Francisco, CA
- Signature
- /s/ Sanam Pangali, Attorney-in-Fact
- All insider transactions
- Transactions in reports broken out by “transaction date” reported in original SEC filing, see here for transactions aggregated across transaction date
Holdings reported by Martin Babler:
| Company | Role | Class | Num Shares | Value | Price $ | Report Date | Ownership |
|---|---|---|---|---|---|---|---|
| ALUMIS INC. | President, CEO and Chairman, Director | Common Stock | 106,454 | $374,718 | $3.52 | 29 Jul 2025 | By Trust |
| ALUMIS INC. | President, CEO and Chairman, Director | Common Stock | 3,000 | $10,560 | $3.52 | 29 Jul 2025 | Direct |
| ALUMIS INC. | President, CEO and Chairman, Director | Stock Option (Right to Buy) | 745,875 | 26 Jan 2026 | Direct | ||
| Prelude Therapeutics Inc | Director | Director Stock Option (Right to Buy) | 38,000 | 12 Jun 2025 | Direct | ||
| Neoleukin Therapeutics, Inc. | Director | Stock Option (Right to Buy) | 25,000 | 08 Jun 2023 | Direct | ||
| 89bio, Inc. | Director | Stock Option (Right to Buy) | 0 | 30 Oct 2025 | Direct |
Insider Reports Filed by Martin Babler
| Symbol | Company | Period | Transactions | Value $ | Form Type | Role | Filing Time |
|---|---|---|---|---|---|---|---|
| ALMS | ALUMIS INC. | 26 Jan 2026 | 1 | $0 | 4 | President, CEO and Chairman, Director | 28 Jan 2026, 19:21 |
| ETNB | 89bio, Inc. | 30 Oct 2025 | 2 | $0 | 4 | Director | 30 Oct 2025, 20:14 |
| ALMS | ALUMIS INC. | 29 Jul 2025 | 2 | $0 | 4 | President, CEO and Chairman, Director | 31 Jul 2025, 21:05 |
| PRLD | Prelude Therapeutics Inc | 12 Jun 2025 | 1 | $0 | 4 | Director | 13 Jun 2025, 16:13 |
| ALMS | ALUMIS INC. | 01 Apr 2025 | 1 | +$100,733 | 4 | President, CEO and Chairman, Director | 03 Apr 2025, 18:05 |
| ALMS | ALUMIS INC. | 18 Feb 2025 | 1 | $0 | 4 | President, CEO and Chairman, Director | 20 Feb 2025, 18:30 |
| ETNB | 89bio, Inc. | 03 Feb 2025 | 1 | $0 | 4 | Director | 05 Feb 2025, 16:01 |
| ALMS | ALUMIS INC. | 27 Jun 2024 | 21 | $0 | 4 | President, CEO and Chairman, Director | 01 Jul 2024, 16:35 |
| ALMS | ALUMIS INC. | 27 Jun 2024 | 0 | $0 | 3 | President, CEO and Chairman, Director | 27 Jun 2024, 16:02 |
| PRLD | Prelude Therapeutics Inc | 14 Jun 2024 | 1 | $0 | 4 | Director | 18 Jun 2024, 16:11 |
| ETNB | 89bio, Inc. | 02 May 2024 | 1 | $0 | 4 | Director | 03 May 2024, 16:01 |
| ETNB | 89bio, Inc. | 13 Apr 2024 | 0 | $0 | 3 | Director | 23 Apr 2024, 16:01 |
| PRLD | Prelude Therapeutics Inc | 16 Jun 2023 | 1 | $0 | 4 | Director | 21 Jun 2023, 16:11 |
| NGNE | Neoleukin Therapeutics, Inc. | 08 Jun 2023 | 1 | $0 | 4 | Director | 09 Jun 2023, 16:24 |
| PRLD | Prelude Therapeutics Inc | 17 Jun 2022 | 1 | $0 | 4 | Director | 22 Jun 2022, 16:13 |
| NGNE | Neoleukin Therapeutics, Inc. | 12 May 2022 | 1 | $0 | 4 | Director | 16 May 2022, 18:22 |
| PRLD | Prelude Therapeutics Inc | 19 Jul 2021 | 1 | $0 | 4 | Director | 20 Jul 2021, 20:30 |
| PRLD | Prelude Therapeutics Inc | 19 Jul 2021 | 0 | $0 | 3 | Director | 20 Jul 2021, 20:26 |
| NGNE | Neoleukin Therapeutics, Inc. | 11 May 2021 | 1 | $0 | 4 | Director | 13 May 2021, 17:36 |